Lineage Cell Therapeutics Inc (LCTX)

1.33 -0.02  -1.48% NYSE AM Nov 23, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
03/12/2021 Earnings Lineage Cell Therapeutics Inc Fourth Quarter Earnings for 2020 Release
03/12/2021 Misc Lineage Cell Therapeutics Inc Fourth Quarter Earnings Conference Call for 2020
11/04/2020 Earnings Lineage Cell Therapeutics Inc Third Quarter Earnings Result for 2020
11/04/2020 16:30 EST Misc Lineage Cell Therapeutics Inc Third Quarter Earnings Conference Call for 2020
09/22/2020 07:30 PDT Misc Lineage Cell Therapeutics Inc Annual General Meeting for 2019
08/06/2020 17:30 EDT Misc Lineage Cell Therapeutics Inc Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Lineage Cell Therapeutics Inc Second Quarter Earnings Result for 2020
05/07/2020 16:30 EDT Misc Lineage Cell Therapeutics Inc First Quarter Earnings Conference Call for 2020
05/07/2020 Earnings Lineage Cell Therapeutics Inc First Quarter Earnings Result for 2020
03/12/2020 16:30 EDT Misc Lineage Cell Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.lineagecell.com
  • Investor Relations URL: http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-IRHome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Mar. 12, 2021
  • Last Earnings Release: Nov. 04, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.